Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Millenium Studying Velcade/Rituxan Combo For Treatment Of NHL

This article was originally published in The Pink Sheet Daily

Executive Summary

Millennium and development partner Johnson & Johnson have initiated a Phase III trial evaluating Velcade (bortezomib) in combination with Genentech/Biogen Idec's Rituxan (rituximab) in the treatment of refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma, the companies announced April 18
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS064018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel